Registry Studies

Descriptive Information

Due to a growing and ageing population, cases of benign prostatic hyperplasia (BPH) have
been on a steady rise. Studies show that by age 80, 90% of men experience BPH.[1] Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few
decades there has been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. The purpose of
this study is to create an ongoing prospective registry to record demographic data and clinical
outcomes after medical therapy or different surgical interventions for BPH. The specific aims
of the registry are to analyse demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various
surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal
treatments of BPH.
The ongoing global registry will provide important baseline data, functional outcomes, and
complications following medical and/or surgical intervention for men with symptomatic BPH.
The intention of the registry is to provide real world usage data that may be used for future
investigations. It will allow providers to identify areas of interest, areas of unusually low usage
or areas of unusual preference on a global scale. It will also shed light on global preferences
for unimodal or multimodal approaches to treatments.

The purpose of this study is to develop a global, multi-centre BPH registry tracking baseline
data with follow-up data for at least 3 years, and thereby analyse demographic patterns, comorbidities, exacerbation, severity, and intervention selection for patients undergoing surgical treatments for BPH, to assess practice patterns (region-specific) for various surgical treatments for BPH, and to assess key outcomes (efficacy and safety) for surgical treatments of
BPH. The ongoing global registry will provide important baseline data, functional outcomes
and complications following medical and/or surgical intervention for men with symptomatic
BPH. It aims to facilitate the identification of areas of interest for underrepresented regions
and guide the implementation of regionally specific and relevant RCTs.

Comparing mean score of the following measures at baseline through follow-up:
Efficacy measures
• IPSS
• QoL
Safety measures
• PVR
• Complications

Efficacy measures
• Prostate volume (cc)
• Qmax
Sexual function measures
• SHIM
• MSHQ-EjD

Recruitment Information

Records and cases of all men ≥18 with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry.

•  A clinical history consistent with Benign Prostatic Hyperplasia
• Prescribed medication or surgical intervention for BPH

• Patients <18 years old
• Patient with no planned intervention

Centers/Contacts

Publications/Documents